HK Stock Market Move | KEYMED BIO-B(02162) surged over 7%, Gilead has agreed to acquire the holding company Ouro Medicines through a merger.

KEYMED BIO-B(02162) up over 7%, as of the time of writing, up 7.63%, at 54.3 Hong Kong dollars, with a turnover of 4.0454 million Hong Kong dollars. In terms of news, KEYMED BIO-B announced that the company holds approximately 15% minority interest in Ouro Medicines through its wholly-owned subsidiary Yibridge Hong Kong. This equity is accounted for in the company's consolidated financial statements at fair value and changes in value are included in the current period profit or loss. Ouro Medicines has notified the company that on March 23, 2026, the buyer Gilead Sciences, Inc. has agreed to acquire Ouro Medicines through a merger. As of December 31, 2025, the Group has recorded unrealized fair value gains of $1 million from its equity in Ouro Medicines. Expected benefits from the merger include: an initial payment of approximately $250 million; and potential milestone payments of up to approximately $70 million, with a total amount of up to approximately $320 million, depending on the achievement of regulatory and performance milestones. The actual amount recorded in the Group's comprehensive income statement will be subject to review, so it may differ from the figures in this announcement. Upon receipt of this amount, it will further strengthen the company's cash reserves, to accelerate the commercialization of core products and the development of potential pipeline.